Temozolomide

目录号:S1237 别名: CCRG81045, NSC 362856

Temozolomide Chemical Structure

Molecular Weight(MW): 194.15

Temozolomide(TMZ)是一种单功能的SN-1烷化剂,修饰DNA环上的氮原子以及环外氧基团。在生理pH值下,TMZ转化为活性产物MTIC、降解为methyldiazonium cation,后者再将甲基转移到DNA, 阻碍DNA复制启动,诱使细胞凋亡,是一种DNA损伤诱导剂。

规格 价格 库存 购买数量  
RMB 521.97 现货
RMB 574.37 现货
RMB 1411.95 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的6个实验数据:

  • C57BL/6 mice were implanted in the striatum with citrine-GL26-Cherry-HMGB1, which were stably transfected to express the YFP citrine and HMGB1 fused to red fluorescent protein cherry. Fourteen days later, they were treated with saline, Ad-TK+Ad-Flt3L, or Ad-TK+Ad-Flt3L+TMZ (temozolomide). Five days after treatment, the cellular location of cherry-HMGB1 in these cells was assessed by confocal microscopy. Arrows, tumor cells (green) with cytoplasmic HMGB1 (red).

    Clin Cancer Res 2014 20(6), 1555-65. Temozolomide purchased from Selleck.

    Talazoparib and temozolomide exhibit marked combinatorial efficacy in PDXs. A, Western blot against MGMT by near-infrared imaging in PDX models.

    Clin Cancer Res, 2017, 23(2):523-535. Temozolomide purchased from Selleck.

  • J Control Release, 2018, 269:245-257. Temozolomide purchased from Selleck.

    Viability of U87 cells(A) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs temozolomide (TMZ) and Bliss interaction index (B) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 400 μM TMZ(A) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-18.. Temozolomide purchased from Selleck.

  • Cells were plated and 12 h after plating were treated with MMF (5 µM), FTY720 (50 nM), Temozolomide (TMZ, 3 µM) or in combination as indicated for 12 h. Cell viability was assessed by live / dead assay.

    Cancer Biol Ther, 2014, 15(12):1646-57. Temozolomide purchased from Selleck.

    Establishment of TMZ-resistant (TR) GBM cell lines. a-d, Evaluation of temozolomide resistance in four glioblastoma cell lines. Cells were cultured in the presence of 5-600 μM of TMZ. A dose-dependent association between the survival rate of cells and TMZ concentration can be observed. Each group was cultured for 24 h in the presence of different concentrations of TMZ, followed by an evaluation of IC50 for TMZ inhibited growth in A172-TR/A172, U118-TR/U118, U251-TR/U251 and U87-TR/U87

    Neurochem Res, 2016, 41(12):3192-3205. Temozolomide purchased from Selleck.

产品安全说明书

DNA/RNA Synthesis抑制剂选择性比较

生物活性

产品描述 Temozolomide(TMZ)是一种单功能的SN-1烷化剂,修饰DNA环上的氮原子以及环外氧基团。在生理pH值下,TMZ转化为活性产物MTIC、降解为methyldiazonium cation,后者再将甲基转移到DNA, 阻碍DNA复制启动,诱使细胞凋亡,是一种DNA损伤诱导剂。
特性 Methazolastone是第二代烷化剂。
靶点
DNA replication [1]
(L-1210, L-1210/BCNU cells)
体外研究

Methazolastone引起DNA碱不稳定位点的形成,其在L-1210和L-1210/BCNU细胞系中以相似数量存在,并且以相似比率修复。在L-1210中,methazolastone诱导细胞阻滞在SL-G2-M期,但在L-1210/BCNU中无此作用。[1]对化疗敏感与耐受的细胞(D54-R 和 U87-R)对Methazolastone的敏感性在高氧情况下被显著增强。Methazolastone和高氧均与ERK p44/42 MAPK (Erk1/2)磷酸化的增加相关,但是在D54-R细胞中增加程度较低,表明Erk1/2可能参与高氧与Methazolastone介导的细胞死亡的调节。高氧增强Methazolastone诱导细胞凋亡在GBM细胞中产生的细胞毒性,可能是通过MAPK相关的途径发挥作用。[2] Methazolastone诱导单核细胞中DNA损伤应答通路ATM-Chk2 和ATR-Chk1,导致p53活化。[3]长期Methazolastone暴露导致获得性Methazolastone耐药,并提高miR-21表达。[4] Methazolastone治疗引起内质网(ER)应激,增加GADD153和GRP78蛋白质表达,并减少caspase 12前体蛋白质。Methazolastone通过线粒体损伤和内质网应激依赖机制诱导自吞噬,以保护神经胶质瘤细胞。[5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly M1[5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvPS4w1QCCq NV\3bmFMUUN3ME2xN|kvOjEkgJpCtgKBkTVwOUWg{txO NYe3R5RmOjV7NkCyPFI>
KellyCis83 NVP4cYpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIG5bFU1QCCq NUHHSJVoUUN3ME2yOVEvODEkgJpCtgKBkTF3Lke1JO69VQ>? MmW0NlU6PjB{OEK=
SK-N-AS MkflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTnZ5luPDhiaB?= MYjJR|UxRTJ{Nz63NQKBkcLz4pEJNlIvOTVizszN M{nuOVI2QTZyMkiy
SK-N-ASCis24 NHHqS|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkS4OFghcA>? MY\JR|UxRTR6MD62NQKBkcLz4pEJNVAyNjF3IN88US=> NV7Qd3dIOjV7NkCyPFI>
CHP-212 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYO0PEBp MmLyTWM2OD15Lkm35qCKyrIkgJmwMlY6KM7:TR?= MXGyOVk3ODJ6Mh?=
CHP-212Cis100 MmX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2G4XVQ5KGh? M2rYXWlEPTB;OT61OgKBkcLz4pEJNE45QCEQvF2= NHi0R4gzPTl4MEK4Ni=>
U87  MYnGeY5kfGmxbjDBd5NigQ>? Mn\TNVAxKM7:TR?= MVmyOE04OiCq MkDCbY5lfWOnczDEZ3IyKGW6cILld5Nqd25? MoPFNlU5ODh6Nki=
LN229 M{fuWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYGwMVUxKM7:TR?= MXTJR|UxRTF4IN88US=> NGm1V5AzPTd3MEK3Ny=>
TR-LN229 MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jLOFAuPTBizszN MnXpTWM2OD15NzFOwG0> Mnf6NlU4PTB{N{O=
U87  M3HmOmFxd3C2b4Ppd{BCe3OjeR?= MlvNNQKBmzJyMPMAjeK2VQ>? NYTDNIJYOjRiaB?= M3nnRYVvcGGwY3XzJGNSKGmwZIXj[YQh[XCxcITvd4l{ MmjLNlU3QDF4Nki=
U251MG M4fVOGFxd3C2b4Ppd{BCe3OjeR?= NESzRlgyODEEoN88US=> NETEclA1QCCq NFjaW|JRSlN? MmfFbY5lfWOnczDhdI9xfG:|aYO= MlHVNlU3QDB2NkS=
U87MG MUnBdI9xfG:|aYOgRZN{[Xl? NWX5doRqOTBywrFOwG0> NHLB[2Q1QCCq NGG1bWRRSlN? NFO4V2tqdmS3Y3XzJIFxd3C2b4Ppdy=> MVeyOVY5ODR4NB?=
U87 NEHBN|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPQNGE2PTBvM{WwJO69VQ>? NUe3e5lCPDkEoHlCpC=> MonLbY5pcWKrdIOgZ4VtdCCpcn;3eIghe2yrZ3j0cJk> MmjtNlU2PTR{MkO=
U118  Ml7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUG1NE0{PTBizszN M37tc|Q5yqCqwrC= NXLPPI1lcW6qaXLpeJMh[2WubDDndo94fGhic3zp[4h1dHl? MXSyOVU2PDJ{Mx?=
U87 MXnGeY5kfGmxbjDBd5NigQ>? MkDsNlUxNzN3MDFOwG0> NH7TRm81QMLiaNMg NH3NZlZmdmijbnPld{BVVVhvaX7keYNm\CCyLWDLR{1x[W5iZHXjdoVie2V? M1\KSVI2PTV2MkKz
U118  MYjGeY5kfGmxbjDBd5NigQ>? NIW2cHMzPTBxM{WwJO69VQ>? NILBS3o1QMLiaNMg Ml24[Y5p[W6lZYOgWG1ZNWmwZIXj[YQheC2SS1OtdIFvKGSnY4LlZZNm NWLo[4R5OjV3NUSyNlM>
U87 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmL6NlUxNzN3MDFOwG0> NHfTWGg1QMLiaNMg MlLhbY5kemWjc3XzJJRp\SCyZYLj[Y51[WenIH;mJINmdGy|IHnuJHMh[W6mIFeyM23DqGOxdILlZZRm\CC5aYToJHROYA>? MlLrNlU2PTR{MkO=
A375 M4naZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWL5UHpiPDkEoHlCpC=> MnzRTWM2OD1{NkWg{txO MnnqNlU2OjR3NUK=
A2058 M{TRU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITadZY1QMLiaNMg NWTndpBqUUN3ME2xNkDPxE1? MWeyOVUzPDV3Mh?=
M238 MoLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVe0POKhcMLi MnzrTWM2OD12MDFOwG0> MX[yOVUzPDV3Mh?=
M249 MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPPOFjDqGkEoB?= NFrXW4ZKSzVyPUK1OEDPxE1? NX23SWlbOjV3MkS1OVI>
M21 MlLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jMdlQ5yqCqwrC= MkLDTWM2OD1{MkGg{txO NInLU5gzPTV{NEW1Ni=>
U251 M3fPSmN6fG:2b4jpeJkhSXO|YYm= M{\aXVIxKM7:TdMg M{O2[lQ5yqCqwrC= NYjMSmJoemWmdXPl[JMhfGinIIDldoNmdnSjZ3XzJI9nKGOxbH;ubYV{KG[xcn3l[C=> MkLWNlU1OzR|OEG=
LN229 NVnPNllUS3m2b4TvfIl1gSCDc4PhfS=> M{TxeFIxKM7:TdMg MnexOFjDqGkEoB?= MljmdoVlfWOnZIOgeIhmKHCncnPlcpRi\2W|IH;mJINwdG:waXXzJIZwem2nZB?= NFTEOZczPTR|NEO4NS=>
U373MG-LUC NWLLNm03T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoWxO|IhcA>? NVOwSlhSUUN3ME62NFAh|ryP M2O5Z|I2PDNzOUWz
U87  NGDUWXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXWyOU0zODBizszN NGPNZ2w1QMLiaNMg NHTjb2pqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MknlNlU1ODB5NEW=
U251 Mnz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrCSnp3OjVvMkCwJO69VQ>? NXnQPZBRPDkEoHlCpC=> MWLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NHT0[JQzPTRyMEe0OS=>
U251 MknUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPFNVAxNTRyMDFOwG0> MoHBO|IwQTZiaB?= M{DWd5Rp\SCjboTpMZBzd2yrZnXyZZRqfmViZX\m[YN1KGOjbjDi[UBmdmijbnPl[EBjgSCpb4PzfZBwdCCnbnjhcoNm\CEEoB?= MYKyOVM4PTJ5MR?=
U373 M2rRfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXuxNFAuPDByIN88US=> NFzsV5E4Oi97NjDo M3WyV5Rp\SCjboTpMZBzd2yrZnXyZZRqfmViZX\m[YN1KGOjbjDi[UBmdmijbnPl[EBjgSCpb4PzfZBwdCCnbnjhcoNm\CEEoB?= MWOyOVM4PTJ5MR?=
U343 MlLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTNWlB2OTByLUSwNEDPxE1? MYK3Nk86PiCq NU[3VnpNfGinIHHueIkueHKxbHnm[ZJifGm4ZTDl[oZm[3RiY3HuJIJmKGWwaHHuZ4VlKGK7IHfvd5N6eG:uIHXubIFv[2WmINMg NGS1R|EzPTN5NUK3NS=>
U87MG-luc2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3QNVAxNTRyMDFOwG0> NHq2SZE4Oi97NjDo NWf4T|NmfGinIHHueIkueHKxbHnm[ZJifGm4ZTDl[oZm[3RiY3HuJIJmKGWwaHHuZ4VlKGK7IHfvd5N6eG:uIHXubIFv[2WmINMg MkjCNlU{PzV{N{G=
U87 MnjFSpVv[3Srb36gRZN{[Xl? MmfvNlAxKM7:TR?= Mlm2OFghcA>? M2myTolv[3KnYYPld{BDWkOFMzDtVm5CKGW6cILld5Nqd25? M3rBb|I2OzN5N{Kx
U251 NIrEc2NHfW6ldHnvckBCe3OjeR?= NVn6eZRjOjByIN88US=> NF2yRmE1QCCq MmX5bY5kemWjc3XzJGJTS0N|IH3SUmEh\XiycnXzd4lwdg>? NImzbHAzPTN|N{eyNS=>
A172 MXnGeY5kfGmxbjDBd5NigQ>? NYXBU3Z2OjByIN88US=> NF3uWpM1QCCq NYO3bWltcW6lcnXhd4V{KEKUQ1OzJI1TVkFiZYjwdoV{e2mxbh?= MoHvNlU{Ozd5MkG=
U251 MkHPSpVv[3Srb36gRZN{[Xl? MWGyNFAh|ryP NHXKRlk1QCCq MnPGbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGJTS0FzLDDCVmNCOixiUlHEOVEh[W6mIF\BUmNFOg>? NW\reIZJOjV|M{e3NlE>
A172 NHW2T|lHfW6ldHnvckBCe3OjeR?= MorWNlAxKM7:TR?= M4\GWFQ5KGh? MmLlbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGJTS0FzLDDCVmNCOixiUlHEOVEh[W6mIF\BUmNFOg>? MmHwNlU{Ozd5MkG=
U87 Ml:1SpVv[3Srb36gRZN{[Xl? M2PQcVIxOCEQvF2= NIHjXJkzPC95Mj:xNlAhcA>? NIDqRnBqdmO{ZXHz[ZMh|rOKMlHYJIZw[2liZn;ycYF1cW:wIITpcYUu\GWyZX7k[Y51dHl? NGHl[lczPTN|N{eyNS=>
U251 MkTySpVv[3Srb36gRZN{[Xl? M2HYdlIxOCEQvF2= NGTudlUzPC95Mj:xNlAhcA>? NVjtWpFIcW6lcnXhd4V{KM7|SELBXEBnd2OrIH\vdo1ifGmxbjD0bY1mNWSncHXu[IVvfGy7 NFy5dZozPTN|N{eyNS=>
A172 MVHGeY5kfGmxbjDBd5NigQ>? M3u2WlIxOCEQvF2= NVf3ZmpVOjRxN{KvNVIxKGh? NVHTc3FncW6lcnXhd4V{KM7|SELBXEBnd2OrIH\vdo1ifGmxbjD0bY1mNWSncHXu[IVvfGy7 NX\jVpQ5OjV|M{e3NlE>
SNB19V M4Hrcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7rO{Bl NF;oNZRFVVOR MXfHTVUxRTN3LkhCtVEzKM7:TR?= NHPPd4kzPTJ5N{S0NS=>
SNB19M MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHexTZc4KGR? NVvoOFRZTE2VTx?= MU\HTVUxRTR4OT65xtE5QCEQvF2= NHrWOWkzPTJ5N{S0NS=>
SNB19VR NVrTcIR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LoO|ch\A>? MofpSG1UVw>? MkX1S2k2OD1{OECuNuKyOThizszN M1vnflI2Ojd5NESx
U373V M2T6NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU[3JIQ> MYnEUXNQ NWLDSZl1T0l3ME22PE4xyrF|MjFOwG0> MYCyOVI4PzR2MR?=
U373M NWCzd4ZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\KUVch\A>? MXnEUXNQ NWP4SndFT0l3ME2zOlgvP8LzOE[g{txO NVruc5cxOjV{N{e0OFE>
U373VR NFfXV4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITBdIY4KGR? NXfEdphoTE2VTx?= NYXLNppDT0l3ME2yPFgvQMLzM{Og{txO MWmyOVI4PzR2MR?=
U87MG NUi3WVRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF:0N4Y4KGR? MmjtSG1UVw>? NUTRV3FyT0l3ME2zPE4{yrF{MDFOwG0> NVXudHN[OjV{N{e0OFE>
HCT116 MmXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYC3JIQ> NIrqR3lFVVOR M{D0NWdKPTB;NUe5MlnDuTN{IN88US=> Ml\BNlUzPzd2NEG=
DLD1 NEe0TI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLuO{Bl M2\zd2ROW09? NXH5WHU3T0l3ME21NFEvPMLzOUOg{txO NWDIZZJROjV{N{e0OFE>
MRC5 MnzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4q0Nlch\A>? MXjEUXNQ NGnnWnRIUTVyPUS0PU41yrF6IN88US=> NXOwTIJzOjV{N{e0OFE>
SNB19V  NIX4SnFHfW6ldHnvckBCe3OjeR?= MU[xNFAh|ryPwrDUUXo> NWrQOJA6OC15MjDo MV3pcoNz\WG|ZYOg{tNJOkG[IHX4dJJme3Orb36gZoV1f2WnbjCxOkBidmRiN{KgbC=> MmPGNlUzPzd2NEG=
T98G  M3vDUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEf5VGY2NzFyL{G1JO69VQ>? NFzOfYEzPMLiaB?= NWCwbWwycW6mdXPld{Bk\WyuIHTlZZRpKGSxc3Wt[IVx\W6mZX70cJkh[W[2ZYKgZ49v[2:vaYThcpQufGWvb4rvcI9ucWSnIIfpeIghVlCnNj3QSHQ> MWOyOVI3Ojl4MR?=
U251  M4XTVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvlbGs2NzFyL{G1JO69VQ>? NILiOIUzPMLiaB?= MkHNbY5lfWOnczDj[YxtKGSnYYToJIRwe2VvZHXw[Y5l\W62bImgZYZ1\XJiY3;uZ49ucXSjboSteIVud3qxbH;tbYRmKHerdHigUnBmPi2SRGS= MmS4NlUzPjJ7NkG=
T98G  NFHL[JNHfW6ldHnvckBCe3OjeR?= M4HIcVE2KM7:TR?= MnTWNlTDqGh? NYn4RYg2cW6lcnXhd4V{KESQQT3mdoFodWWwdHH0bY9vKGmwIF7Q[VYuWESWIITy[YF1\WRiZ3zpc41iKGOnbHzz NUnEZ4Y1OjV{NkK5OlE>
U251  MXnGeY5kfGmxbjDBd5NigQ>? MnPYNVUh|ryP NYG5fohZOjUEoHi= MnTzbY5kemWjc3XzJGRPSS2ocnHncYVvfGG2aX;uJIlvKE6SZU[tVGRVKHS{ZXH0[YQh\2yrb33hJINmdGy| MV[yOVI3Ojl4MR?=
U-87 MG MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\t[25EPzJiaB?= NX62dZl[UUN3ME2wMlk{KG2PwrC= NGT1S3EzPTJ2NUOzNi=>
U-118 MG NU\iOWJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWro[3hEPzJiaB?= MU\JR|UxRTFwMEWgcW3DqA>? NUD5VJV2OjV{NEWzN|I>
U87 M1rERmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXiXFU{OjRiaB?= M1O3[mlEPTB;Mk[wMlM1KM7:TdMg NGXr[ZAzPTF5M{KzNy=>
U87 GSLCs NETkd|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\MXG0zPCCq Ml:5TWM2OD15Nk[uNVEh|ryPwrC= NVvodHVQOjVzN{OyN|M>
U87MG NFLjVoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrnO|IhcA>? Mn7MTWM2OD1zNT62NlUh|ryPwrC= NFrKN|IzPTB3MEmxOS=>
U251 NV3ESFNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDnNVAxNTRyMDFOwG0> MVu0PEBp NFWzPYdFVVOR NYq0WpQ4cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MYWyOFYzOzd|Nh?=
U87 MnO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nFUlExOC12MECg{txO M2fzN|Q5KGh? NWjKeZdKTE2VTx?= NV73WG1XcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NX7zVFNXOjR4MkO3N|Y>
MDA-MB-231-br Mn\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\CNE0yOCEQvF2= MVq0PEBp M2nlTGROW09? M3\QRolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MWmyOFYzOzd|Nh?=
HCC-1937 MlXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjlW5gxNTNyMDFOwG0> Mn;5OFghcA>? MlP5SG1UVw>? MnfJbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M3LwdVI1PjJ|N{O2
MDA-MB-231 NXjhTIt{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXmzZpVbOC12MDFOwG0> MX[0PEBp MYLEUXNQ NYDzS|BYcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NXn0TFF6OjR4MkO3N|Y>
MDA-MB-468 NF7wV5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTSNE02ODBizszN NGW4cHQ1QCCq M3:3fGROW09? MV;pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MYiyOFYzOzd|Nh?=
T47D NGDtXWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjZXnBOOC1zMECg{txO MnvlOFghcA>? NGq4RZZFVVOR MVPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> Ml;2NlQ3OjN5M{[=
MCF7 NX;zc45lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH6xeo8xNTFyMECg{txO NHi4OlQ1QCCq MYPEUXNQ NYLJPVY1cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NV;JbmJkOjR4MkO3N|Y>
Hs683 M1X1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUiwMVExODBizszN M2LVWlk3KGh? M{HBS2lEPTB;MUK4Mlkh|ryP NH3xcmQzPDR7NUmwOy=>
U87 NUC2U5djT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2KxfVAuOTByMDFOwG0> MXy5OkBp Mk\hTWM2OD1zOD60OUDPxE1? MoL6NlQ1QTV7MEe=
LNZ308 NGOwWWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW[wMVExODBizszN Mn\2PVYhcA>? NXPWTXdkUUN3ME2zNlYvPyEQvF2= M{PjS|I1PDl3OUC3
U87 NXnBPGN[SXCxcITvd4l{KEG|c3H5 Mny1NVAxKM7:TR?= M1T2[lQ5KGh? M1jyT2ROW09? M4DXN4lv[3KnYYPld{B1cGViY3HzdIF{\S1|L{egZYN1cX[rdIm= MVyyOFQ5OTV6Nh?=
U251  NV\meow6SXCxcITvd4l{KEG|c3H5 M2T3eFExOCEQvF2= NXPIOlFpPDhiaB?= MULEUXNQ MlPZbY5kemWjc3XzJJRp\SClYYPwZZNmNTNxNzDhZ5Rqfmm2eR?= MWKyOFQ5OTV6Nh?=
U251 M4P3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\UNlQhcA>? MmDFTWM2OD16Nj6yPgKBkcLz4pEJNU42QCEQvF2= NVLzco0xOjR|Mk[5OVQ>
U251 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrMNWgyPDhiaB?= MVHJR|UxRTd3LkO05qCKyrIkgJmxMlAzKM7:TR?= NHT3[m8zPDN{Nkm1OC=>
U251 MmrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVO3e|J5PzJiaB?= NX[2NYR{UUN3ME23Nk41OuLCidMx5qCKOS52NTFOwG0> M2\afFI1OzJ4OUW0
U251 NGrCZ3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7UPVYhcA>? NIPhSndKSzVyPU[5Mlgz6oDLwsJihKk{NjB2IN88US=> NVv6VHltOjR|Mk[5OVQ>
T98G NIWyRlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnqVZJqOC15NUCg{txO NVnmcpBrPzJxOU[gbC=> MXrpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NILhZ44zPDN{NEC4NC=>
U251-MG MlnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWWwMVgxOCEQvF2= MonsO|IhcA>? MlLLbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M4HJR|I1ODl|NkOw
D54-MG NIjWcZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrYR4pSOC16MECg{txO MojmO|IhcA>? MmDGbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M2\6fFI1ODl|NkOw
SHG-44 MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml:5NVAuOjByIN88US=> NXHz[nB4QTZiaB?= M{HhWGlEPTB;OT63N{DDuSB{LkGyJO69VQ>? NUfDXJFVOjRyNkW1Olk>
U373  NXXwXY1sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn60NVAuOjByIN88US=> M3SyWFk3KGh? MV3JR|UxRTFyLkGzJOKyKDFwMEKg{txO MYCyOFA3PTV4OR?=
HT-29  MW\GeY5kfGmxbjDBd5NigQ>? NUjSXnhMPTByIN88US=> NYn0WpQ1OjRxNEigbC=> M3;hcIVvcGGwY3XzJJRp\SCuZY\lcJMhd2ZizsOtTFJCYMLi MXOyOFA{QDB4OB?=
PC-3  NW\2RYtFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTmNE0zPSEQvF2= Mk\oOFghcA>? MnjibY5pcWKrdIOgZ4VtdCCpcn;3eIghf2irY3igZ4FvKGKnIIDveIVvfGmjdHXkJIJ6KGy7Y3;w[Y5m NU\Bc3lkOjN5NE[5N|Q>
PC-3  NULodI1xSXCxcITvd4l{KEG|c3H5 M1vrU|I2KM7:TR?= M{H4VVQ5KGh? Ml7rbY5lfWOnczDhdI9xfG:|aYOge4hq[2hiY3HuJIJmKHCxdHXueIlifGWmIHL5JIx6[2:yZX7l MWOyN|c1Pjl|NB?=
T98G MnO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\GS|UxNTRyMDFOwG0> MUSxOFQhcA>? NV2ydZM1cW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NIr5NFUzOzdzNUS5PS=>
U87-MG M4rMeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DMe|ExOCEEtV2= MV63NkBp MVHpcohq[mm2czDj[YxtKGe{b4f0bEB4cGmlaDDjZY4h[mViZX7oZY5k\WRiYomgS3RD M1vEU|I{Pjl4N{i4
U251-MG NUDGRZB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\BNlUyODBiwsXN MlXXO|IhcA>? NVn0PGVxcW6qaXLpeJMh[2WubDDndo94fGhid3jpZ4gh[2GwIHLlJIVvcGGwY3XkJIJ6KEeWQh?= MV6yN|Y6Pjd6OB?=
LNT-229 M171fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXWcmdmOy1zMECg{txO MV:yOEBp M1nFUolvcGmkaYTzJINtd26xZ3XubYMhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MVGyN|Y3PzZ|Mh?=
T98G MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTwNVAuPzByIN88US=> NVnFZWZWOjRiaB?= MUfpcohq[mm2czDjcI9vd2enbnnjJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NFv3UoMzOzZ4N{[zNi=>
U87  M4LhSmZ2dmO2aX;uJGF{e2G7 MlfYNVAxKML3TR?= MljIN{Bp Mlrt[YxmfmG2ZYOgeIhmKGyndnXsd{Bw\iCyQ3jrNUBidmRicFPob|I> NVj2VGFUOjN4Nke0Olk>
HCT116 MXLGeY5kfGmxbjDBd5NigQ>? NFPBemIyODBiwsXN NWmwcG9iOyCq MmrkbY5lfWOnczD0bIUhS2itMTDQbI9{eGixconsZZRqd25? MU[yN|Y3PzR4OR?=
HCT3-6 NUTxXlVQTnWwY4Tpc44hSXO|YYm= MnzvNVAxKML3TR?= Mn3kN{Bp NIXTfWZqdmS3Y3XzJJRp\SCFaHuxJHBpd3OyaH;yfYxifGmxbh?= M2jYNVI{PjZ5NE[5
U-87  M2nqS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrrSYMxNTRyIN88US=> NFfGfXoyOiCm M{nI[IlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NXfhdocxOjN4NEW3Nlk>
U-87  MlK1RZBweHSxc3nzJGF{e2G7 M4fPfVAuPDBizszN NH;vdFA{NzZiZB?= MUTpcoR2[2W|IHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> NYLx[HFYOjN4NEW3Nlk>
U-87  MWXGeY5kfGmxbjDBd5NigQ>? MWiwMVQxKM7:TR?= Mmn2N{83KGR? NYHMPIRpcW6mdXPld{BifXSxcHjh[5khcW5iYn;0bEBld3OnLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ M2LLeFI{PjR3N{K5
GB-SCC010 MkW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkC4OEBl M1vFfmlEPTB;MkK2JO69VQ>? NIXoUHgzOzZzMke1OS=>
GB-SCC026 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXhOEBl MlPPTWM2OD13Mz6xJO69VQ>? NV3QcGgxOjN4MUK3OVU>
GB-SCC028 M37hdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUi0JIQ> NHWxeY1KSzVyPUG2O{DPxE1? NEfDdXYzOzZzMke1OS=>
U87 NWfFe|ZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfBR|JVPCCm NFTaZ4JKSzVyPUS1MlIh|ryP M4KwR|I{PjF{N{W1
U87 stem cell MkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTkZXI1KGR? MkDkTWM2OD14Nj63JO69VQ>? MVmyN|YyOjd3NR?=

... Click to View More Cell Line Experimental Data

体内研究 每天腹腔注射40 mg/kg,连续5天(肿瘤移植后1-5天)后,在L-1210 和L-1210/BCNU中,methazolastone分别增加86%和22%的寿命。在L-1210/BCNU中,100 μM 或200 μM治疗后没有作用,仅400 μM methazolastone使细胞在有丝分裂前期产生积聚,但是在L-1210中效果较弱。在L-1210/BCNU中,SL-G2-M期细胞的最大积聚在48-72小时后,大约为30%,未处理的细胞为23%。患有L- 1210白血病的小鼠静脉注射methazolastone (40 mg/kg)时,也会使细胞在SL-G2-M期积聚。而给予相同剂量药物的小鼠L-1210/BCNU细胞中,没有此作用。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:

[1]

+ 展开
  • Cell lines: L-1210 和 L-1210/BCNU 细胞
  • Concentrations: 0 μM -100 μM
  • Incubation Time: 1小时
  • Method:

    L-1210和L-1210/ BCNU细胞以0.2×104 cells/mL接种,并培养24小时。培养基用Methazolastone在37℃下处理1小时,然后用PBS洗涤两次,离心并重新悬浮在新鲜培养基中。对照组和处理试样在48小时时以1:4在新鲜培养基中稀释,第96小时时,以1:2稀释。整个实验中使用这些稀释的细胞浓度介于3×105和8×105/mL之间。该范围内对照组呈对数生长。


    (Only for Reference)
动物实验:

[1]

+ 展开
  • Animal Models: 负荷L-1210 和 L-1210/BCNU细胞的DBA/2小鼠
  • Formulation: 95%乙醇
  • Dosages: 40 mg/kg
  • Administration: 静脉注射给药
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 38 mg/mL (195.72 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+30% PEG 300+ddH2O
2mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 194.15
化学式

C6H6N6O2

CAS号 85622-93-1
稳定性 powder
in solvent
别名 CCRG81045, NSC 362856

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02991456 Recruiting Chemo-radiation Induced Nausea and Vomiting Duke University|Tesaro Inc. October 9 2017 Phase 2
NCT00392171 Completed Glioma|Astrocytoma|Oligodendroglioma|Glioblastoma Merck Sharp & Dohme Corp. June 9 2006 Phase 2
NCT00305864 Completed Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma National Cancer Institute (NCI)|Radiation Therapy Oncology Group February 9 2006 Phase 1|Phase 2
NCT00200161 Completed Glioblastoma|Gliomas Memorial Sloan Kettering Cancer Center|Schering-Plough|Columbia University|Dana-Farber Cancer Institute August 9 2005 Phase 2
NCT03528642 Not yet recruiting Anaplastic Astrocytoma IDH-Mutant|Diffuse Astrocytoma IDH-Mutant|IDH1 Gene Mutation|IDH2 Gene Mutation National Cancer Institute (NCI) February 8 2019 Phase 1
NCT03422445 Recruiting Advanced Melanoma Beijing Cancer Hospital January 8 2018 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

DNA/RNA Synthesis Signaling Pathway Map

相关DNA/RNA Synthesis产品

Tags: 购买Temozolomide | Temozolomide ic50 | Temozolomide价格 | Temozolomide DMSO溶解度 | 采购Temozolomide | Temozolomide生产 | Temozolomide 小鼠 | Temozolomide化学结构 | Temozolomide分子量 | Temozolomide molecular weight | Temozolomide说明书 | Temozolomide供应商 | Temozolomide体内 | Temozolomide细胞系 | Temozolomide浓度 | Temozolomide nmr | Temozolomide核磁 | Temozolomide半数抑制浓度 | Temozolomide体外
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID